CK2β-regulated signaling controls B cell differentiation and function.

Autor: Quotti Tubi, Laura, Mandato, Elisa, Nunes, Sara Canovas, Arjomand, Arash, Zaffino, Fortunato, Manni, Sabrina, Casellato, Alessandro, Macaccaro, Paolo, Vitulo, Nicola, Zumerle, Sara, Filhol, Odile, Boldyreff, Brigitte, Siebel, Christian W., Viola, Antonella, Valle, Giorgio, Mainoldi, Federica, Casola, Stefano, Cancila, Valeria, Gulino, Alessandro, Tripodo, Claudio

Publikováno v: Frontiers in Immunology; 1/11/2023, Vol. 13, p1-25, 25p

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Inactivation of CK1α in multiple myeloma empowers drug cytotoxicity by affecting AKT and β-catenin survival signaling pathways.

Autor: Manni S; Department of Medicine, Hematology and Clinical Immunology Section, University of Padova, Padova, Italy.; Venetian Institute of Molecular Medicine, Padova, Italy., Carrino M; Department of Medicine, Hematology and Clinical Immunology Section, University of Padova, Padova, Italy.; Venetian Institute of Molecular Medicine, Padova, Italy., Manzoni M; Department of Oncology and Hemato-Oncology, University of Milano, Milano, Italy.; Hematology Unit, Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, Milano, Italy., Gianesin K; Department of Medicine, Hematology and Clinical Immunology Section, University of Padova, Padova, Italy.; Venetian Institute of Molecular Medicine, Padova, Italy., Nunes SC; Department of Medicine, Hematology and Clinical Immunology Section, University of Padova, Padova, Italy.; Venetian Institute of Molecular Medicine, Padova, Italy., Costacurta M; Department of Medicine, Hematology and Clinical Immunology Section, University of Padova, Padova, Italy.; Venetian Institute of Molecular Medicine, Padova, Italy., Tubi LQ; Department of Medicine, Hematology and Clinical Immunology Section, University of Padova, Padova, Italy.; Venetian Institute of Molecular Medicine, Padova, Italy., Macaccaro P; Department of Medicine, Hematology and Clinical Immunology Section, University of Padova, Padova, Italy.; Venetian Institute of Molecular Medicine, Padova, Italy., Taiana E; Department of Oncology and Hemato-Oncology, University of Milano, Milano, Italy.; Hematology Unit, Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, Milano, Italy., Cabrelle A; Venetian Institute of Molecular Medicine, Padova, Italy., Barilà G; Department of Medicine, Hematology and Clinical Immunology Section, University of Padova, Padova, Italy.; Venetian Institute of Molecular Medicine, Padova, Italy., Martines A; Immunology and Molecular Oncology Unit, Veneto Institute of Oncology, IOV-IRCCS- Padova, Italy., Zambello R; Department of Medicine, Hematology and Clinical Immunology Section, University of Padova, Padova, Italy.; Venetian Institute of Molecular Medicine, Padova, Italy., Bonaldi L; Immunology and Molecular Oncology Unit, Veneto Institute of Oncology, IOV-IRCCS- Padova, Italy., Trentin L; Department of Medicine, Hematology and Clinical Immunology Section, University of Padova, Padova, Italy.; Venetian Institute of Molecular Medicine, Padova, Italy., Neri A; Department of Oncology and Hemato-Oncology, University of Milano, Milano, Italy.; Hematology Unit, Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, Milano, Italy., Semenzato G; Department of Medicine, Hematology and Clinical Immunology Section, University of Padova, Padova, Italy.; Venetian Institute of Molecular Medicine, Padova, Italy., Piazza F; Department of Medicine, Hematology and Clinical Immunology Section, University of Padova, Padova, Italy.; Venetian Institute of Molecular Medicine, Padova, Italy.

Publikováno v: Oncotarget [Oncotarget] 2017 Feb 28; Vol. 8 (9), pp. 14604-14619.